Press the FDA to reconsider and reverse its denial of a Pediatric Rare Disease Priority Review Voucher for a gene therapy treating sickle cell disease.

Tim Scott · South Carolina · Republican

oversight impact 0.45 specificity 0.86 extraction confidence 78%

Contest this claim

Occurrences

urging the agency to reconsider and reverse a prior decision denying a Pediatric Rare Disease Priority Review Voucher (PRV) for a gene therapy treating sickle cell disease (SCD).

Scott led a bicameral letter asking FDA leadership to revisit and correct the prior denial of a PRV for a sickle cell disease gene therapy.

Sen. Tim Scott leads bicameral letter urging FDA to reconsider gene therapy decision
secondary · other · model gpt-5.5

Evidence

The report says Bluebird's acquisition followed the FDA's final denial of Bluebird's appeal for a priority review voucher tied to Lyfgenia.

This is the clearest located status signal: the FDA did not reverse the Lyfgenia priority review voucher denial; the appeal was finally denied before the 2025 acquisition deal.

never same_term

Bluebird Bio to Be Acquired by Carlyle Group, SK Capital
secondary · model gpt-5.5 · confidence 90%

Contest this evidence item

FDA approved Lyfgenia for patients 12 and older with sickle cell disease and listed Priority Review, Orphan Drug, Fast Track, and RMAT designations, but not a rare pediatric disease voucher award.

The official approval record identifies Lyfgenia as the relevant sickle-cell gene therapy and shows FDA approval did not include a rare pediatric disease priority review voucher award in the agency's listed actions.

never same_term

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
secondary · model gpt-5.5 · confidence 78%

Contest this evidence item

Assessments

never same_term

The promised outcome required FDA reconsideration and reversal of the rare pediatric disease priority review voucher denial for the sickle-cell gene therapy. FDA approved Lyfgenia without awarding that voucher, and later reporting indicates Bluebird's appeal was finally denied rather than reversed. Because Tim Scott remained in the same federal Senate term during these events and the requested agency outcome did not occur, this is not delivered. The provided evidence does not establish a serious candidate-driven attempt warranting an effort badge.

provider codex_cli · model gpt-5.5 · confidence 88%